Factor This Power Engineering
Live Events
DTECH⢠Events
POWERGEN®
Calendar
Resource Center
Webinars
Podcasts
White Papers
Contribute Content
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Project Development
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Resource Center
Webinars
Podcasts
Whitepapers
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
1.091
+0.041 (+3.94%)
Streaming Delayed Price
Updated: 1:39 PM EST, Nov 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
November 12, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Provides Strategic Update
October 09, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 29, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 26, 2025
Via
ACCESS Newswire
Lexaria Attending BIO International Convention
June 05, 2025
Via
ACCESS Newswire
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
February 27, 2025
Via
ACCESS Newswire
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
September 19, 2025
Via
ACCESS Newswire
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
August 27, 2025
Via
ACCESS Newswire
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
August 14, 2025
Via
ACCESS Newswire
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
August 06, 2025
Via
ACCESS Newswire
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
July 28, 2025
Via
ACCESS Newswire
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
February 24, 2025
Via
ACCESS Newswire
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
February 20, 2025
Via
ACCESS Newswire
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
February 11, 2025
Via
ACCESS Newswire
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
July 23, 2025
Via
ACCESS Newswire
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
June 23, 2025
Via
ACCESS Newswire
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
June 11, 2025
Via
ACCESS Newswire
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
May 12, 2025
Via
ACCESS Newswire
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
April 28, 2025
Via
ACCESS Newswire
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
February 06, 2025
Via
ACCESS Newswire
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
February 05, 2025
Via
ACCESS Newswire
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
January 15, 2025
Via
ACCESSWIRE
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
April 25, 2025
Via
ACCESS Newswire
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
April 23, 2025
Via
ACCESS Newswire
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
April 03, 2025
Via
ACCESS Newswire
Lexaria's Human GLP-1 Study #5 Begins Dosing
April 02, 2025
Via
ACCESS Newswire
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
March 18, 2025
Via
ACCESS Newswire
Lexaria's Registered GLP-1 Study #4 Begins Dosing
December 19, 2024
Via
ACCESSWIRE
Lexaria Releases Annual Letter from the CEO
January 30, 2025
Via
ACCESS Newswire
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
January 14, 2025
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
